2019 Volume 65 Issue 6 Pages 175-180
We reviewed 38 cases of recurrent or metastatic squamous-cell carcinoma of the head and neck treated with Nivolumab in our hospital and reported the cases that developed adverse events associated with Nivolumab monotherapy. The clinical responses to Nivolumab were partial response in 9 cases, stable disease in 10 cases, and progressive disease in 12 cases. The response rate and clinical benefit were 27.3% and 57.6%. The 1-year overall survival rate and 1-year progression-free survival rate were 32.3% and 18.2%, respectively. The most common immune-related adverse events (irAEs) were liver dysfunction (n=2) and thyroid dysfunction (n=2). Other irAEs included hyperthyroidism, arthritis, and interstitial pneumonia (n=1, each). Careful follow-up is recommended in patients treated with Nivolumab monotherapy.
